# Ruxolitinib as GVHD Prophylaxis in AA Patients

> **NCT05914714** · PHASE2 · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 46 (estimated)

## Conditions studied

- The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA

## Interventions

- **DRUG:** Ruxolitinib 5 MG BID Oral Tablet

## Key facts

- **NCT ID:** NCT05914714
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05914714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05914714, "Ruxolitinib as GVHD Prophylaxis in AA Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05914714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*